PM-LGSOC-01 Cells

PM-LGSOC-01 is a cell line derived from peritoneal metastasis of a low-grade serous ovarian carcinoma (LGSOC). This cell line was established as part of a comprehensive research model that also included a patient-derived xenograft (PDX). The creation of PM-LGSOC-01 involved orthotopic engraftment via subperitoneal tumor slurry injection in SCID/Beige mice, leading to an early-stage transplantable peritoneal metastasis (PM)-PDX model. Histological analysis confirmed that both the PM-PDX and PM-LGSOC-01 cells retained the micropapillary and cribriform growth patterns typical of LGSOC, with tumor budding, and expression of markers such as PAX8 and WT1. Genetic analysis showed that the primary tumor, the PM, and the cell line share a KRAS c.35 G > T (p.Gly12Val) mutation, making this model relevant for studying LGSOC progression and treatment response, particularly in relation to the MAPK pathway. PM-LGSOC-01 exhibits key characteristics relevant for preclinical research. It has a doubling time of approximately 42 hours in early passages, which decreased to 23 hours in later stages of cell culture, and has been maintained for over 100 in vitro passages. The cell line demonstrates epithelial morphology with cobblestone-like organization and high cell-cell adhesion. However, it shows limited response to platinum-based chemotherapy but is highly sensitive to paclitaxel (IC50: 6.3 ? 2.2 nM). Additionally, PM-LGSOC-01 is particularly sensitive to the MEK inhibitor trametinib (IC50: 7.2 ? 0.5 nM), both in vitro and in vivo, reflecting the impact of the KRAS mutation on therapeutic responses. PM-LGSOC-01 serves as a valuable tool for investigating LGSOC, particularly in the context of drug resistance, tumorigenicity, and sensitivity to targeted therapies like MEK inhibitors. Its use in developing personalized treatment approaches for low-grade serous ovarian carcinoma is critical, given the poor responsiveness of LGSOC to conventional chemotherapy compared to high-grade serous ovarian carcinoma (HGSOC). Reproductive system cancer cell lines, Ovary, Low grade-serous ovarian carcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1